RxDoctor Payments Data

Kianna Lyons, NP

Acute Care · Saint Clair Shores, MINPI 1134435878

Payments from drug & device makers

$2,235in general payments, 2019–2025

Across 41 payments — averaging $54.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Enterra Medical, Inc.$1K
  • Ardelyx, Inc.$218
  • AbbVie$185
  • Johnson & Johnson$164
  • Takeda Pharmaceuticals U.S.A., Inc.$81
  • Bristol Myers Squibb$59
  • plus $140 from 6 others

What the payments were for

  • Grants$1888%
  • Travel & lodging$1,01846%
  • Food & beverage$93042%
  • Education$1004%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,235 in reported general payments places this provider in the 85th percentile of 567 acute care providers in Michigan.

See all acute care providers in Michigan

Medicare billing

Part B allowed, 2024
$25,163
Medicare patients
157
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide104$97,729
IbsrelaTenapanor Hcl33$85,552
MotegrityPrucalopride Succinate76$62,897
XifaxanRifaximin25$55,791
MovantikNaloxegol Oxalate23$15,827
Lubiprostone87$15,531
Scopolamine33$3,882
Esomeprazole Magnesium47$3,602
Mirtazapine42$1,641
Omeprazole92$1,531
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl51$1,020
Famotidine84$1,010
Rabeprazole Sodium35$924
Dicyclomine Hcl59$900
Pantoprazole Sodium37$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$185$97,729104 claims
Ardelyx, Inc.Ibsrela$218$85,55233 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$81$62,89776 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$52$55,79125 claims
Redhill Biopharma Inc.Movantik$15$15,82723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 567 acute care providers in Michigan.

Other acute care in Saint Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →